Figure S1. CHOICE study design. CHOICE, Crohn’s Disease WHO Failed Prior Infliximab to Collect Safety Data and Efficacy via Patient-Reported Outcome Measures; eow, every other week. Minimum study duration was 8 weeks. Data were analyzed through week 24.

Figure S2. Mean SIBDQ total scores by week of adalimumab therapy: all adalimumab and patients with and without fistula healing. Mean SIBDQ total scores showed statistically significant and rapid improvements that were maintained through week 24 (all adalimumab-treated patients, < 0.05 vs. baseline). Greater scores indicate better HRQOL. HRQOL, health-related quality of life; SIBDQ, short inflammatory bowel disease questionnaire.

Figure S3. Mean WPAI scores by week of adalimumab therapy: patients with and without fistula healing. Decreases indicate less impairment. (a) Absenteeism. (b) Presenteeism. (c) TWPI. (d) TAI. TAI, total activity impairment; TWAI, total work productivity impairment; WPAI, Work Productivity and Activity Impairment Questionnaire.

Table S1. Infliximab history.

Table S2. Summary of infectious SAEs.

Table S3. Mean change from baseline in SIBDQ domain scores by visit: all adalimumab.

Table S4. Mean change from baseline in WPAI outcomes by visit.

APT_4466_sm_fS1.TIF16KSupporting info item
APT_4466_sm_fS2.TIF16KSupporting info item
APT_4466_sm_fS3a.TIF14KSupporting info item
APT_4466_sm_fS3b.TIF13KSupporting info item
APT_4466_sm_fS3c.TIF14KSupporting info item
APT_4466_sm_fS3d.TIF14KSupporting info item
APT_4466_sm_tS1-4.doc130KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.